Company intelligence / Profile preview

Delta4

Vienna, Vienna, Austriadelta4womeninaction.org ↗

Ownership: Private
Development stage: Preclinical

Overview

Delta4 leverages its proprietary Hyper-C AI platform to identify novel therapeutic indications for existing drugs with known safety profiles. The company has demonstrated success in uncovering new potential uses for compounds such as Iguratimod, advancing some candidates into pre-clinical testing—particularly in rare/orphan disease areas like terminal kidney failure. Their approach aims to accelerate clinical development by de-risking candidate selection through computational modeling and big data analytics.

Therapeutic areas: ImmunologyRare DiseasesNephrology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

4P025

Preclinical

Beyond the preview

Go deeper on Delta4.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Delta4.

Explore the full profile